Equibles does not estimate personal net worth.
Get an email with a short summary when Vivos Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get VVOS alertsR. Kirk Huntsman is recorded as CEO at Vivos Therapeutics, Inc. (VVOS). The newest filing on record that lists R. Kirk Huntsman as CEO at Vivos Therapeutics, Inc. (VVOS) is dated September 29, 2025. The proxy statement of Vivos Therapeutics, Inc. reports total compensation of $1,306,906 for R. Kirk Huntsman in fiscal 2024, including a base salary of $408,700. Disclosed compensation is on record for 5 fiscal years. R. Kirk Huntsman has spoken on 10 earnings calls across 1 company, most recently for Vivos Therapeutics, Inc. on August 14, 2026. Vivos Therapeutics, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Vivos Therapeutics, Inc. includes Roman Franklin (CFO), Anja Krammer (Board Member), Gregg C. E. Johnson (Board Member) and 4 others.
“I'd like to thank Brad Ammon in particular today for his time here in the company for the last six or seven years. Brad has been a key part of our management team, and we're going to miss him.”
“It was just over a month ago that we reported our 2025 annual results. from that report some investors became concerned at the drop in revenue during our fourth quarter 2025. we explained that the primary contributing factors of decreased provider office days and insurance headwinds were both temporary and correctable…”
“The third quarter of 2025 will go down in the history of Vivos as a watershed quarter and an inflection point in the trajectory of our business.”
“2025 was a period of significant change for Vivos Therapeutics, Inc. and the culmination of nearly two years of laying the groundwork for our new model.”
“And thank you all for joining us on today's conference call. In a moment, I'll turn the call back to Brad, who will walk us through the highlights of our first quarter of 2025 financial and operating results.”
Start not stated–present
Last confirmed September 29, 2025
Medical Devices · Healthcare
CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Vivos Therapeutics, Inc. (VVOS) | Chief Executive Officer | $408,700 | $1,306,906 |
| 2023 | Vivos Therapeutics, Inc. (VVOS) | Chief Executive Officer | $463,393 | $657,701 |
| 2022 | Vivos Therapeutics, Inc. (VVOS) | Chief Executive Officer | $384,853 | $937,850 |
| 2021 | Vivos Therapeutics, Inc. (VVOS) | Chief Executive Officer | $344,229 | $1,077,149 |
| 2020 | Vivos Therapeutics, Inc. (VVOS) | Chief Executive Officer | $251,784 | $455,336 |
